Skip to Content
Morningstar

Taro Pharmaceutical Industries Ltd TARO

Morningstar Rating
Unlock
Stock XNYS Rating as of
$42.48 +0.28 (0.66%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
TARO is trading at a 20% discount.
Price
$42.41
Fair Value
$26.31
Uncertainty
High
1-Star Price
$37.73
5-Star Price
$91.32
Economic Moat
Yqqdw
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TARO is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$42.20
Day Range
$42.13–42.49
52-Week Range
$24.69–43.40
Bid/Ask
$41.50 / $45.00
Market Cap
$1.60 Bil
Volume/Avg
28,900 / 44,676

Key Statistics

Price/Earnings (Normalized)
33.78
Price/Sales
2.61
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
1,554
Website
https://www.taro.com

Competitors

Valuation

View More
Metric
TARO
NVS
PRGO
Price/Earnings (Normalized)
 33.7814.2512.12
Price/Book Value
 0.905.060.89
Price/Sales
 2.614.090.91
Price/Cash Flow
 20.8313.579.12
Price/Earnings
TARO
NVS
PRGO

Financial Strength

Metric
TARO
NVS
PRGO
Quick Ratio
 3.030.610.94
Current Ratio
 3.600.901.79
Interest Coverage
 —11.320.95
Quick Ratio
TARO
NVS
PRGO

Profitability

Metric
TARO
NVS
PRGO
Return on Assets (Normalized)
 2.15%13.39%3.23%
Return on Equity (Normalized)
 2.62%31.09%7.32%
Return on Invested Capital (Normalized)
 0.92%19.67%5.60%
Return on Assets
TARO
NVS
PRGO
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
MKKGY
Merck KGaA ADRPtswfbwmbJcsmpm$69.8 Bil
ZTS
Zoetis Inc Class ADnljmlglzRqyh$68.9 Bil
HLN
Haleon PLC ADRPtkrscnpRhgdk$37.7 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRDrcxxmwnXhrhp$14.8 Bil
VTRS
Viatris IncNgqgwbtmLgqp$13.6 Bil
RDY
Dr Reddy's Laboratories Ltd ADRYskssvkzdDkmx$11.9 Bil
CTLT
Catalent IncWdlhbthjmNtmblm$10.1 Bil
PRGO
Perrigo Co PLCZldkrbxzKpjw$4.2 Bil
CURLF
Curaleaf Holdings IncWscbjcqBlkg$3.6 Bil
PBH
Prestige Consumer Healthcare IncLdhkqbjgzZjzsjq$3.5 Bil

Sponsor Center